ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,308.13
0.09%
Dow Jones
39,806.77
-0.49%
US Dollar vs MXN
16.5714
0.10%
Brent Oil
83.115
-0.50%
Bitcoin
71,267.03
-0.26%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Marinus Pharmaceuticals Inc (MRNS)

  7. Marinus Pharmaceuticals Inc (MRNS) Noticias

MRNS

Marinus Pharmaceuticals (MRNS)

Marinus Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:MRNS
FechaHoraFuenteTítuloSímboloCompañía
17/05/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
17/05/202406:00Business WireMarinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex ProgramNASDAQ:MRNSMarinus Pharmaceuticals Inc
08/05/202406:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRNSMarinus Pharmaceuticals Inc
08/05/202406:00Business WireMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
02/05/202407:00Business WireMarinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare ConferenceNASDAQ:MRNSMarinus Pharmaceuticals Inc
01/05/202407:00Business WireMarinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:MRNSMarinus Pharmaceuticals Inc
15/04/202406:00Business WireMarinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
05/04/202415:00Business WireMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:MRNSMarinus Pharmaceuticals Inc
27/03/202407:41Business WireMarinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant ReviewNASDAQ:MRNSMarinus Pharmaceuticals Inc
05/03/202415:14Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MRNSMarinus Pharmaceuticals Inc
05/03/202415:01Business WireMarinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
22/02/202415:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRNSMarinus Pharmaceuticals Inc
21/02/202406:00Business WireMarinus Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:MRNSMarinus Pharmaceuticals Inc
20/02/202406:00Business WireMarinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024NASDAQ:MRNSMarinus Pharmaceuticals Inc
14/02/202415:18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRNSMarinus Pharmaceuticals Inc
04/01/202406:01Business WireMarinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business UpdateNASDAQ:MRNSMarinus Pharmaceuticals Inc
20/11/202315:01Business WireMarinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD StudyNASDAQ:MRNSMarinus Pharmaceuticals Inc
14/11/202315:05Business WireMarinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:MRNSMarinus Pharmaceuticals Inc
07/11/202306:01Business WireMarinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
07/11/202306:00Business WireMarinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CVNASDAQ:MRNSMarinus Pharmaceuticals Inc
24/10/202306:01Business WireMarinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023NASDAQ:MRNSMarinus Pharmaceuticals Inc
10/10/202315:01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MRNSMarinus Pharmaceuticals Inc
21/09/202315:00Business WireMarinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare ConferenceNASDAQ:MRNSMarinus Pharmaceuticals Inc
19/09/202307:00Business WireMarinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event NASDAQ:MRNSMarinus Pharmaceuticals Inc
12/09/202315:00Business WireMarinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023NASDAQ:MRNSMarinus Pharmaceuticals Inc
17/08/202315:01Business WireMarinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023NASDAQ:MRNSMarinus Pharmaceuticals Inc
10/08/202306:01Business WireMarinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
31/07/202306:01Business WireMarinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency DisorderNASDAQ:MRNSMarinus Pharmaceuticals Inc
27/07/202306:01Business WireMarinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023NASDAQ:MRNSMarinus Pharmaceuticals Inc
29/06/202305:01Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:MRNSMarinus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MRNS

Su Consulta Reciente

NYSE
MCD
McDonalds
USOTC
ADDYY
Adidas (QX)
NYSE
BAC
Bank of America
COIN
SOLUSD
Solana
CCOM
US500
US 500
NYSE
DIS
Walt Disney
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
TSLA
Tesla
NYSE
XOM
Exxon Mobil
AMEX
XLV
Health Care Select Sector
NASDAQ
AAPL
Apple
USOTC
RHHBY
Roche (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
MRK
Merck
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
BTCUSD
Bitcoin
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados